VIVE (VIVE) Stock Price & Analysis
VIVE (VIVE) rose 0.00% to USD 0 as of July 26, 2026 at 15:38 UTC, according to Nexqual real-time market data.
VIVE last closed at USD 0; the session ranged USD 0–0 on volume of 2,330 shares. Market capitalization is $2,144, with a 52-week range of USD 0–0 (PNK). Source: Nexqual, July 26, 2026 at 15:38 UTC.
Key Statistics (as of July 26, 2026 at 15:38 UTC)
| Price | USD 0 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0 |
| Open | USD 0 |
| Day Range | USD 0 – 0 |
| 52-Week Range | USD 0 – 0 |
| Volume | 2,330 shares |
| Market Cap | $2,144 |
| Exchange | PNK |
Technical Analysis (VIVE)
Nexqual's technical model rates VIVE "STRONG SELL" based on 0 bullish and 5 bearish signals across 125 daily candles, as of July 26, 2026 at 15:38 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 100 (overbought) |
| vs SMA50 | Below (USD 0) |
| MACD | 0 (negative) |
Analyst Ratings (VIVE)
Wall Street analysts rate VIVE "None", per Nexqual as of July 26, 2026 at 15:38 UTC.
| Consensus Rating | None |
|---|
Earnings (VIVE)
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2022-09-30 | USD -0.59 vs est -0.66 ▲ beat |
| 2022-06-30 | USD -0.62 vs est -0.67 ▲ beat |
| 2022-03-31 | USD -0.67 vs est -0.68 ▲ beat |
| 2021-12-31 | USD -0.72 vs est -0.6 ▼ miss |
Source: Nexqual, July 26, 2026 at 15:38 UTC.
Financials & Fundamentals (VIVE)
| Total Revenue | $6.83M |
|---|---|
| Revenue Growth (YoY) | +4.20% |
| Gross Margin | +16.39% |
| Operating Margin | -276.84% |
| Profit Margin | +0.00% |
| ROE | -210.99% |
| Debt / Equity | 507.94 |
| Current Ratio | 0.89 |
| Total Cash | $5.91M |
| Total Debt | $6.01M |
| Free Cash Flow | $-7.57M |
Source: Nexqual, July 26, 2026 at 15:38 UTC.
Financial Health Score (VIVE)
Nexqual rates VIVE's overall financial health "Weak" across five dimensions, as of July 26, 2026 at 15:38 UTC.
| Growth | Strong — Revenue +17% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Critical — $6M cash vs $6M debt |
| Cash Flow | Weak — FCF negative: -$8M, burning cash |
| Efficiency | Critical — ROE -211%, ROA -62.1% |
Ownership (VIVE)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +0.00% |
| Shares Outstanding | 10.72M |
| Float | 10.72M |
| Short % of Float | +3.49% |
Source: Nexqual, July 26, 2026 at 15:38 UTC.
Leadership (VIVE)
VIVE is led by Martin Kerber P.E., Vice President of Research, Development & Operations, per Nexqual as of July 26, 2026 at 15:38 UTC.
| Vice President of Research, Development & Operations | Martin Kerber P.E. |
|---|---|
| Vice President of Global Marketing | Gary Kaiser |
| Senior Vice President of Regulatory & Quality Affairs | Suzon D. Lommel (age 67) |
Major Backers & Investors (VIVE)
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 0.56% |
Source: Nexqual, July 26, 2026 at 15:38 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| XBIO | Xenetic Biosciences, Inc. | USD 2.64 | ▼ 1.12% |
| CFOR | OpGen, Inc. | USD 18 | ▼ 10% |
| PRPO | Precipio, Inc. | USD 23.68 | ▲ 0.85% |
| BIMI | BIMI International Medical Inc. | USD 0 | ▲ 0% |
| VTVT | vTv Therapeutics Inc. | USD 30.73 | ▼ 2.97% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 26, 2026 at 15:38 UTC. This page is informational and not investment advice.